Category: Drug Safety Alerts
-
Xeljanz: Drug-induced Peripheral Neuropathy as Possible Xeljanz Side Effect in 2 RA Patients
Reports of Rheumatoid Arthritis Patients on Xeljanz Experiencing Secondary Neurological Adverse Events (Posted by Tom Lamb at Drug Injury Watch) As we have written about previously, according to the FDA, some of the generally recognized…
-
Padcev Skin Reaction Side Effects SJS and TEN: From No Warning to “Black Box” in Less Than 2 Years
Bladder Cancer Drug Padcev is Linked to Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in 2021 (Posted by Tom Lamb at Drug Injury Watch) Padcev (enfortumab vedotin-ejfv), an injection drug for intravenous use, was…
-
Elmiron and Maculopathy: Increased Risk of Ocular Complications in Long-Term, High-Dose Elmiron Use
Two Recent Medical Articles on Vision Side Effects of Elmiron (pentosan polysulfate sodium, or PPS) for Interstitial Cystitis (Posted by Tom Lamb at Drug Injury Watch) Chronic use of Elmiron (pentosan polysulfate sodium, or PPS)…
-
Xeljanz: FDA Warnings Updated: There are Higher Rates of Blood Clots and Deaths for Both Doses of Xeljanz, Now
JAK Inhibitors Xeljanz, Olumiant, and Rinvoq Get Drug Label Changes and Drug Use Limitations in September 2021 (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, the FDA released this alerting news…
-
Invokana, Farxiga, Jardiance, Other SGLT2 Inhibitors Associated With Retinal Vein Occlusion
Increased Risk for This New Vision/Eyes Side Effect Highest in Elderly Patients and Chronic Kidney Disease Patients (Posted by Tom Lamb at Drug Injury Watch) In June 2021 it was reported that Invokana, Farxiga, and…
-
Beovu Vision Loss Side Effects Continue to Plague Novartis, Ending 3 Key Clinical Trials in May 2021
And Novartis "has yet to identify the root cause behind Beovu’s safety problem", According to a News Report (Posted by Tom Lamb at Drug Injury Watch) Starting back in February 2020, when the American Society…
-
First Monotherapy Ocrevus PML Case Report: Patient Used Ocrevus for 2 Years Without Prior Immunotherapy
Compare 9 Earlier Cases of PML in MS Patients After Ocrevus Treatments: Those Involved Previous Tysabri and/or Gilenya Use (Posted by Tom Lamb at Drug Injury Watch) Pharmaceutical company Genentech knew about the first monotherapy…